170 related articles for article (PubMed ID: 36370634)
1. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Bennett JL; Aktas O; Rees WA; Smith MA; Gunsior M; Yan L; She D; Cimbora D; Pittock SJ; Weinshenker BG; Paul F; Marignier R; Wingerchuk D; Cutter G; Green A; Hartung HP; Kim HJ; Fujihara K; Levy M; Katz E; Cree BAC;
EBioMedicine; 2022 Dec; 86():104321. PubMed ID: 36370634
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
Fujihara K; Kim HJ; Saida T; Misu T; Nagano Y; Totsuka N; Iizuka M; Kido S; Terata R; Okumura K; Hirota S; Cree BAC
Mult Scler Relat Disord; 2023 Nov; 79():104938. PubMed ID: 37769428
[TBL] [Abstract][Full Text] [Related]
3. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Lublin FD; Drappa J; Barron G; Madani S; Ratchford JN; She D; Cimbora D; Katz E;
Lancet; 2019 Oct; 394(10206):1352-1363. PubMed ID: 31495497
[TBL] [Abstract][Full Text] [Related]
4. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Green AJ; Aktas O; Hartung HP; Lublin FD; Williams IM; Drappa J; She D; Cimbora D; Rees W; Smith M; Ratchford JN; Katz E; Cree BAC;
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33771837
[TBL] [Abstract][Full Text] [Related]
5. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Nie T; Blair HA
CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
[TBL] [Abstract][Full Text] [Related]
6. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Flanagan EP; Levy M; Katz E; Cimbora D; Drappa J; Mealy MA; She D; Cree BAC
Mult Scler Relat Disord; 2022 Jan; 57():103352. PubMed ID: 35158461
[TBL] [Abstract][Full Text] [Related]
7. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Cree BA; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Williams IM; Drappa J; She D; Cimbora D; Rees W; Ratchford JN; Katz E
Mult Scler; 2021 Nov; 27(13):2052-2061. PubMed ID: 33538237
[TBL] [Abstract][Full Text] [Related]
9. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
J Tullman M; Zabeti A; Vuocolo S; Dinh Q
Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
[TBL] [Abstract][Full Text] [Related]
10. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA;
J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Rensel M; Zabeti A; Mealy MA; Cimbora D; She D; Drappa J; Katz E
Mult Scler; 2022 May; 28(6):925-932. PubMed ID: 34595983
[TBL] [Abstract][Full Text] [Related]
12. Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder).
Ali F; Sharma K; Anjum V; Ali A
Curr Drug Discov Technol; 2022; 19(1):e140122193419. PubMed ID: 34011260
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
Yan L; Wang B; She D; Mitchell B; Criste R; Cimbora D; Katz E; Rees WA
Br J Clin Pharmacol; 2022 Aug; 88(8):3803-3812. PubMed ID: 35332558
[TBL] [Abstract][Full Text] [Related]
14. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder.
Siebert N; Duchow A; Paul F; Infante-Duarte C; Bellmann-Strobl J
Drugs Today (Barc); 2021 May; 57(5):321-336. PubMed ID: 34061127
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
16. Inebilizumab: First Approval.
Frampton JE
Drugs; 2020 Aug; 80(12):1259-1264. PubMed ID: 32729016
[TBL] [Abstract][Full Text] [Related]
17. Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
Weinshenker BG; Wingerchuk DM; Green AJ; Bennett JL; Kim HJ; Pittock SJ; Fujihara K; Paul F; Cutter G; Marignier R; Aktas O; Hartung HP; She D; Smith M; Rees W; Patterson K; Cimbora D; Katz E; Cree BA
Mult Scler; 2023 Jul; 29(8):945-955. PubMed ID: 37282545
[TBL] [Abstract][Full Text] [Related]
18. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
Kim HJ; Aktas O; Patterson KR; Korff S; Kunchok A; Bennett JL; Weinshenker BG; Paul F; Hartung HP; Cimbora D; Smith MA; Mittereder N; Rees WA; She D; Cree BAC
Ann Clin Transl Neurol; 2023 Dec; 10(12):2413-2420. PubMed ID: 37804003
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
[TBL] [Abstract][Full Text] [Related]
20. Peripheral CD19
Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]